CN109963596B - 长效多特异性分子和相关方法 - Google Patents
长效多特异性分子和相关方法 Download PDFInfo
- Publication number
- CN109963596B CN109963596B CN201780063877.7A CN201780063877A CN109963596B CN 109963596 B CN109963596 B CN 109963596B CN 201780063877 A CN201780063877 A CN 201780063877A CN 109963596 B CN109963596 B CN 109963596B
- Authority
- CN
- China
- Prior art keywords
- compound
- antibody
- peg
- antibodies
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111260981.XA CN114249830A (zh) | 2016-10-17 | 2017-10-11 | 长效多特异性分子和相关方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662408865P | 2016-10-17 | 2016-10-17 | |
US62/408,865 | 2016-10-17 | ||
PCT/US2017/056118 WO2018075308A1 (en) | 2016-10-17 | 2017-10-11 | Long acting multi-specific molecules and related methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111260981.XA Division CN114249830A (zh) | 2016-10-17 | 2017-10-11 | 长效多特异性分子和相关方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN109963596A CN109963596A (zh) | 2019-07-02 |
CN109963596A8 CN109963596A8 (zh) | 2019-10-15 |
CN109963596B true CN109963596B (zh) | 2021-09-07 |
Family
ID=62019040
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780063877.7A Active CN109963596B (zh) | 2016-10-17 | 2017-10-11 | 长效多特异性分子和相关方法 |
CN202111260981.XA Pending CN114249830A (zh) | 2016-10-17 | 2017-10-11 | 长效多特异性分子和相关方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111260981.XA Pending CN114249830A (zh) | 2016-10-17 | 2017-10-11 | 长效多特异性分子和相关方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11065342B2 (zh) |
EP (1) | EP3525824A4 (zh) |
JP (2) | JP6982070B2 (zh) |
KR (2) | KR102396847B1 (zh) |
CN (2) | CN109963596B (zh) |
AU (2) | AU2017346401B2 (zh) |
CA (2) | CA3143066A1 (zh) |
WO (1) | WO2018075308A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6982070B2 (ja) * | 2016-10-17 | 2021-12-17 | シェンチェン エンドゥリング バイオテック,リミテッド | 長期作用型多重特異性分子および関連した方法 |
KR20220009380A (ko) * | 2019-05-17 | 2022-01-24 | 선전 엔듀어링 바이오테크 리미티드 | 표적 면역요법을 위한 절단 가능한 사이토카인이 있는 이중특이적 t-세포 연계체 |
CN114502200A (zh) * | 2020-04-15 | 2022-05-13 | 深圳康源久远生物技术有限公司 | 抗体药物缀合物 |
US11510994B2 (en) | 2021-01-29 | 2022-11-29 | EqIP, LLC | Linkers for improving the stability of bioconjugates and the selectivity of payload release |
KR20230159463A (ko) * | 2021-03-19 | 2023-11-21 | 선전 엔듀어링 바이오테크 리미티드 | Cd3 및 cd19에 대해 이중 특이성을 갖는 페길화된 t 세포 인게이저 |
US20230322996A1 (en) * | 2021-11-08 | 2023-10-12 | Life Technologies As | Polymer-interaction molecule conjugates and methods of use |
WO2023151679A1 (en) * | 2022-02-11 | 2023-08-17 | Shenzhen Enduring Biotech , Ltd. | Pegylated antibody hydroxyl-bearing drug conjugate |
WO2024022384A1 (en) * | 2022-07-28 | 2024-02-01 | Shenzhen Enduring Biotech , Ltd. | Peg based anti-cd47/anit-pd-l1 bispecific antibody-drug conjugate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015175357A1 (en) * | 2014-05-10 | 2015-11-19 | Sorrento Therapeutics, Inc. | Chemically-locked bispecific antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040018203A1 (en) * | 2001-06-08 | 2004-01-29 | Ira Pastan | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
US7947839B2 (en) * | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
CA2781682A1 (en) * | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
US20110206672A1 (en) * | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
CA2832387A1 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
AU2012301793A1 (en) | 2011-08-30 | 2014-03-20 | Quanta Biodesign, Ltd. | Branched discrette PEG constructs |
US10159735B2 (en) * | 2012-06-26 | 2018-12-25 | The Curators Of The University Of Missouri | Photocleavable drug conjugates |
JP6982070B2 (ja) * | 2016-10-17 | 2021-12-17 | シェンチェン エンドゥリング バイオテック,リミテッド | 長期作用型多重特異性分子および関連した方法 |
-
2017
- 2017-10-11 JP JP2019520623A patent/JP6982070B2/ja active Active
- 2017-10-11 CA CA3143066A patent/CA3143066A1/en active Pending
- 2017-10-11 KR KR1020197009949A patent/KR102396847B1/ko active IP Right Grant
- 2017-10-11 EP EP17862587.7A patent/EP3525824A4/en active Pending
- 2017-10-11 CA CA3036889A patent/CA3036889C/en active Active
- 2017-10-11 KR KR1020227015409A patent/KR102585474B1/ko active IP Right Grant
- 2017-10-11 US US16/341,486 patent/US11065342B2/en active Active
- 2017-10-11 AU AU2017346401A patent/AU2017346401B2/en active Active
- 2017-10-11 CN CN201780063877.7A patent/CN109963596B/zh active Active
- 2017-10-11 WO PCT/US2017/056118 patent/WO2018075308A1/en active Application Filing
- 2017-10-11 CN CN202111260981.XA patent/CN114249830A/zh active Pending
-
2021
- 2021-07-01 AU AU2021204606A patent/AU2021204606A1/en active Pending
- 2021-07-12 US US17/373,296 patent/US20210338832A1/en active Pending
- 2021-11-18 JP JP2021187703A patent/JP2022028830A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015175357A1 (en) * | 2014-05-10 | 2015-11-19 | Sorrento Therapeutics, Inc. | Chemically-locked bispecific antibodies |
Non-Patent Citations (1)
Title |
---|
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia;Craig A Portell et al;《Clinical Pharmacology: Advances and Applications》;20130412;5-11 * |
Also Published As
Publication number | Publication date |
---|---|
CA3036889A1 (en) | 2018-04-26 |
AU2017346401A1 (en) | 2019-04-04 |
CA3036889C (en) | 2022-02-15 |
JP2019537572A (ja) | 2019-12-26 |
CN109963596A8 (zh) | 2019-10-15 |
KR102585474B1 (ko) | 2023-10-06 |
US20210338832A1 (en) | 2021-11-04 |
JP2022028830A (ja) | 2022-02-16 |
US11065342B2 (en) | 2021-07-20 |
EP3525824A4 (en) | 2020-06-10 |
JP6982070B2 (ja) | 2021-12-17 |
CN109963596A (zh) | 2019-07-02 |
KR102396847B1 (ko) | 2022-05-10 |
AU2021204606A1 (en) | 2021-07-29 |
WO2018075308A1 (en) | 2018-04-26 |
EP3525824A1 (en) | 2019-08-21 |
CN114249830A (zh) | 2022-03-29 |
KR20190069412A (ko) | 2019-06-19 |
US20190298844A1 (en) | 2019-10-03 |
KR20220066183A (ko) | 2022-05-23 |
CA3143066A1 (en) | 2018-04-26 |
AU2017346401B2 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109963596B (zh) | 长效多特异性分子和相关方法 | |
US20230104728A1 (en) | Antibody-drug conjugate | |
KR20150030784A (ko) | 공유 결합된 항원-항체 접합체 | |
US20220233711A1 (en) | Bispecific t-cell engager with cleavable cytokines for targeted immunotherapy | |
KR20160101721A (ko) | 공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도 | |
CN114174317A (zh) | 鹅膏毒素抗体-药物缀合物及其用途 | |
CN113045659B (zh) | 抗cd73人源化抗体 | |
JP2024516581A (ja) | 抗ヒトcd73抗体およびその適用 | |
CN110152014B (zh) | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 | |
WO2023151679A1 (en) | Pegylated antibody hydroxyl-bearing drug conjugate | |
CN117430708B (zh) | 一种抗Claudin18.2抗体 | |
WO2024022384A1 (en) | Peg based anti-cd47/anit-pd-l1 bispecific antibody-drug conjugate | |
US20230391867A1 (en) | Long acting bi-specific t cell engagers targeting cd3 and cd47 | |
CN110141666B (zh) | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 | |
CN117624366A (zh) | 5t4纳米抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CI02 | Correction of invention patent application |
Correction item: Inventor Correct: S-M.Liu|D.Wu False: S-M.Liu|D.Wu Number: 27-01 Page: The title page Volume: 35 Correct: S-M.Liu|D.Wu False: S-M.Liu|D.Wu Number: 27-01 Volume: 35 |
|
CI02 | Correction of invention patent application | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200108 Address after: C1105, Yinxing technology building, No. 1301, Guanlan street, Longhua District, Shenzhen, Guangdong Province Applicant after: Shenzhen Kangyuan Jiuyuan Biotechnology Co., Ltd Address before: new jersey Applicant before: Princeton Persistent Biotechnology Company |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |